Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 05/01/18 at 09:59am

Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn't been too rough. To the surprise of no one, its business as usual in the pharma and life sciences industries - Pfizer has kicked the year off with a drug discovery agreement with Arvinas to the tune of £830 million, while Allergan looks to be following in the footsteps of Teva with the announcement of massive staff cuts in order to make cost savings.

But the biggest news with our readers since the beginning of the year is Valeant's £290 million payout to resolve a 2014 case of alleged insider trading.

To celebrate the new year and recap what you may have missed, make sure not to miss our Top Ten stories of 2017.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Pfizer makes $830m drug discovery pact with Arvinas

Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing agreement.

9. Mylan and Biocon biosimilar approval expands to Brazil

Since Mylan and Biocon managed to gain US FDA approval for its Herceptin biosimilar, it has forged ahead in the global market to make up for time lost due to manufacturing issues.

8. FDA approves shock wave wound healing device

Continuing its recent trend to promote innovative new technologies, the FDA has announced that it has approved a medical device that uses shock waves to help promote wound healing in those suffering from diabetes.

7. GW Pharma applies to both EU and US for lead product

GW Pharmaceuticals had a busy festive period, after it announced that it had submitted to both the EU and the US for marketing authorisation on its lead product, Epidiolex.

6. NICE to take another look at Pfizer’s leukaemia drug

NICE rejected Pfizer’s Besponsa on cost-effectiveness grounds, back in August 2017, but it has now revealed that NICE has agreed to return to evaluate the treatment, again.

5. Allergan to axe over 1,000 positions in cost cutting measures

Allergan has announced that it plans to cut away 1,000 existing positions and to remove a further 400 open positions due to expected generic competition on Restatsis.

4. J&J’s predicted blockbuster depression posts P2 data

Johnson & Johnson has revealed Phase 2 data for its treatment for depression, esketamine, and the results are positive - showing substantial benefit beyond standard treatment.

3. Spark’s bright idea on $850,000 blindness gene therapy

Spark Therapeutics knew that it had to think very carefully about where it pitched its price for its inarguably ground-breaking gene therapy to treat a specific kind of blindness, and it has brought an innovative pricing model to try smooth the treatment's path to patients.

2. Diabetes drugs show potential in treating Alzheimer’s

A group of researchers at Lancaster University have identified a drug currently used to treat type 2 diabetes that has shown potential benefit in the treatment of Alzheimer’s disease.

1. Valeant and Pershing take $290m hit over insider trading

Valeant Pharmaceuticals will be hoping it can begin 2018 as a fresh start, after a turbulent few years, to say the least, with the settlement of a case claiming that it had been involved in alleged insider trading in 2014.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches